title: Effectiveness of a pilot intervention to reduce abciximab-related bleeding in patients with acute coronary syndromes.
abstract: OBJECTIVE
  Reducing bleeding events is a priority in patients diagnosed with acute coronary syndromes (ACS). The effectiveness of optimization measures for reducing abciximab-related bleeding was evaluated through the implementation of a pilot program developed by the Pharmacy and the Cardiology Departments at a tertiary-care hospital.
  
  
  METHODS
  Percentage of bleeding events.
  
  
  RESULTS
  Intervention was effective in reducing the incidence of the three factors associated with an increased risk of bleeding between the pre-intervention phase (n = 86) and the post-intervention phase (n = 73): unknown body weight (24.4 vs. 1.4 %, p = 0.0001), overdosing (31.4 vs. 0 %, p < 0.0001) and combination with bivalirudin (12.8 vs. 1.4 %, p = 0.016). Bleeding events associated with these factors were numerically reduced in all three cases but these differences were not statistically significant between both periods.
  
  
  CONCLUSIONS
  The implementation of a multidisciplinary prevention program can reduce situations associated with an increased risk of bleeding in patients treated with abciximab. Larger scale trials are needed to confirm whether such programs can also reduce the incidence of bleeding at a statistically significant level.
authors.affiliation: Pharmacy Department, Instituto de Investigación Sanitaria Gregorio Marañón, Hospital General Universitario Gregorio Marañón, C/Doctor Esquerdo 46, 28007, Madrid, Spain, ana.lorenzo@salud.madrid.org.
authors.forename: Ana
authors.initials: A
authors.lastname: de Lorenzo-Pinto
authors.forename: Héctor
authors.initials: H
authors.lastname: Bueno
authors.forename: Ana
authors.initials: A
authors.lastname: Herranz-Alonso
authors.forename: Jaime
authors.initials: J
authors.lastname: Elizaga-Corrales
authors.forename: Cristina
authors.initials: C
authors.lastname: Pérez-Sanz
authors.forename: Begoña
authors.initials: B
authors.lastname: Cuéllar-Basterrechea
authors.forename: Francisco
authors.initials: F
authors.lastname: Fernández-Avilés
authors.forename: María
authors.initials: M
authors.lastname: Sanjurjo-Sáez
mesh_terms: D000077284:Abciximab; D054058:Acute Coronary Syndrome / Q000188:drug therapy*; D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D000991:Antithrombins / Q000009:adverse effects / Q000627:therapeutic use; D001835:Body Weight; D015331:Cohort Studies; D054796:Drug Dosage Calculations; D004359:Drug Therapy, Combination / Q000009:adverse effects; D005260:Female; D006470:Hemorrhage / Q000139:chemically induced / Q000453:epidemiology / Q000517:prevention & control*; D006629:Hirudins / Q000009:adverse effects; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D015994:Incidence; D008297:Male; D008875:Middle Aged; D010446:Peptide Fragments / Q000009:adverse effects / Q000627:therapeutic use; D010607:Pharmacy Service, Hospital; D010865:Pilot Projects; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use; D012189:Retrospective Studies; D012307:Risk Factors; D013030:Spain / Q000453:epidemiology; D062606:Tertiary Care Centers; D000078329:Workforce
chemical_list: D000911:Antibodies, Monoclonal; D000991:Antithrombins; D006629:Hirudins; D007140:Immunoglobulin Fab Fragments; D010446:Peptide Fragments; D010975:Platelet Aggregation Inhibitors; D011994:Recombinant Proteins; C074619:bivalirudin; D000077284:Abciximab